Healthy Clinical Trial
Official title:
Effects of Plyometric- and Cycle-Based High-Intensity Interval Training on Body Composition, Aerobic Capacity, and Muscle Function in Young Females: a Field-based Group Fitness Assessment
| Verified date | June 2023 |
| Source | Kennesaw State University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The goal of this clinical trial was to compare to different types of high-intensity interval training in young, healthy females. The main questions were: Will changes in body composition differ between the two interventions? Will changes in endurance and muscle performance differ between the two interventions? Participants were randomized to 8 weeks of high-intensity interval training involving body weight, plyometric exercises or cycling only. Researchers compared changes in endurance performance, body composition, and muscle performance to determine if there were differences between groups.
| Status | Completed |
| Enrollment | 30 |
| Est. completion date | November 21, 2018 |
| Est. primary completion date | November 21, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 35 Years |
| Eligibility | Inclusion Criteria: - Between 18-35 years of age - Female - Currently participating in 2-4 days of structured exercise for 30-75 minutes for the last 6 months Exclusion Criteria: - Currently participating in these exercise formats (2x/week within last 3 months) - Engaging in high intensity interval training for more than 30 min/week - Have diagnosed disorders/diseases in the following: cardiovascular, pulmonary, immunological, or metabolic - Current musculoskeletal injuries - Pregnant or think you may be pregnant - Currently taking any non-steroidal anti-inflammatory drug(s) or steroidal drug(s) - Currently a smoker or has consistently smoked within the last year - Has a positive written or verbal pre-study drug screen including alcohol (more than 7 drinks/week), THC/cannabinoids, amphetamines, benzodiazepines, cocaine, opioids, phencyclidine, barbiturates, cotinine. - Currently taking any medication that will significantly affect your heart rate response to exercise - If you miss four or more classes, you will be excluded from the study |
| Country | Name | City | State |
|---|---|---|---|
| United States | Kennesaw State University | Kennesaw | Georgia |
| Lead Sponsor | Collaborator |
|---|---|
| Kennesaw State University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Weekly exercising heart rate | A descriptor of the exercise physiological intensity for both protocols | during 8-week exercise intervention | |
| Other | Weekly exercising perceived effort | Perceived intensity derived from the rating of perceived exertion scale | during 8-week exercise intervention | |
| Other | Calorie consumption at baseline | Amount of calories consumed at beginning and end of protocol | Pre-intervention | |
| Other | Calorie consumption after 8-week intervention | Amount of calories consumed at beginning and end of protocol | At week 9 | |
| Other | Protein consumption at baseline | Amount of protein consumed at beginning and end of protocol | Pre-intervention | |
| Other | Protein consumption after 8-week intervention | Amount of protein consumed at beginning and end of protocol | At week 9 | |
| Other | Peak heart during maximal testing at baseline | The highest heart rate attained during maximal exercise testing | Pre-intervention | |
| Other | Peak heart during maximal testing after 8-week intervention | The highest heart rate attained during maximal exercise testing | At week 9 | |
| Primary | Muscle composition at baseline | echo-intensity value derived from ultrasound that indicates the amount of fat infiltration in muscle | Pre-intervention | |
| Primary | Muscle composition after 8-week intervention | echo-intensity value derived from ultrasound that indicates the amount of fat infiltration in muscle | At week 9 | |
| Secondary | Fat mass at baseline | Amount of fat tissue a person possesses | Pre-intervention | |
| Secondary | Fat mass after 8-week intervention | Amount of fat tissue a person possesses | At week 9 | |
| Secondary | Group average growth hormone response (concentration at microLiters/Liters) at baseline | The acute, exercise-induced response for growth hormone | Pre-intervention | |
| Secondary | Group average growth hormone response (concentration at microLiters/Liters) after 8-week intervention | The acute, exercise-induced response for growth hormone | At week 9 | |
| Secondary | Countermovement jump height at baseline | Height of jump | Pre-intervention | |
| Secondary | Countermovement jump height after 8-week intervention | Height of jump | At week 9 | |
| Secondary | Time to peak torque at baseline | How quickly muscle torque is generated | Pre-intervention | |
| Secondary | Time to peak torque after 8-week intervention | How quickly muscle torque is generated | At week 9 | |
| Secondary | Maximal oxygen consumption at baseline | Standard measure of maximal oxygen consumption or peak aerobic capacity during exercise | Pre-intervention | |
| Secondary | Maximal oxygen consumption after 8-week intervention | Standard measure of maximal oxygen consumption or peak aerobic capacity during exercise | At week 9 | |
| Secondary | Body fat percentage at baseline | Relative amount of body fat a person possesses | Pre-intervention | |
| Secondary | Body fat percentage after 8-week intervention | Relative amount of body fat a person possesses | At week 9 | |
| Secondary | Fat-free mass at baseline | Amount of non-fat tissue a person possesses | Pre-intervention | |
| Secondary | Fat-free mass after 8-week intervention | Amount of non-fat tissue a person possesses | At week 9 | |
| Secondary | Peak torque at baseline | Strength of a muscle | Pre-intervention | |
| Secondary | Peak torque after 8-week intervention | Strength of a muscle | At week 9 | |
| Secondary | Muscle cross-sectional area at baseline | The size of a muscle | Pre-intervention | |
| Secondary | Muscle cross-sectional area after 8-week intervention | The size of a muscle | At week 9 | |
| Secondary | Muscle power at baseline | Product of torque and velocity as determined on a dynamometer | Pre-intervention | |
| Secondary | Muscle power after 8-week intervention | Product of torque and velocity as determined on a dynamometer | At week 9 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |